CRISPR Therapeutics’ CRSP Casgevy, a one-shot gene therapy, was approved in late 2023 and early 2024 across the United States ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is ...

At 22, Daniel Cressy is making history as Louisiana’s first sickle cell gene therapy patient. The treatment could be a cure ...

CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 ...

While Casgevy is currently the only CRISPR-based therapy, several companies are advancing gene-editing treatments using similar technology. Beam Therapeutics BEAM is developing its lead candidate ...

Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing.

Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end of the decade. See why CRSP stock is a Hold.

As Vertex Pharmaceuticals and CRISPR Therapeutics lay the groundwork for the launch of their CRISPR-based gene-editing therapy Casgevy, one doctor who treats sickle cell disease patients is already ...